NCT06325566Phase 3Active not recruiting

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-07Estimated

Enrollment · participants300Estimated

Source updated2026-06-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-17 · 2 fields changed

Primary completion date changed

− Before

~~Oct 2026~~

+ After

Jul 2027

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Degenerative Disc Disease

Treatments or interventions studied

Rexlemestrocel-L + HA mixtureDrug
SalineDrug

Primary outcomes · main study measures

Read the study measures

measure: Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) Score; description: Low back pain intensity will be measured using a VAS ranging from 0-100 millimeter (mm). A score of 0 represents no pain and 100 represents worst possible pain.; timeFrame: Baseline and Month 12; measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); timeFrame: Up to Month 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history